A Study to Test the Safety, Pharmacokinetics, and Efficacy of UCB9741 in Healthy Study Participants and in Study Participants With Atopic Dermatitis

Summary

The purpose of the study is to investigate the safety and tolerability of single-ascending doses of UCB9741 administered by intravenous infusion or subcutaneous injection to healthy study participants and following repeat dosing at a single dose level in study participants with atopic dermatitis. Furthermore, the clinical efficacy outcome in study participants with atopic dermatitis after administration of UCB9741 by intravenous infusion will be investigated.

Timeline

Start

2020-11-27

Primary completion

2024-04-23

Completion

2024-06-06

Outcome

Met primary endpoint

release “At Week 12, a median of 64.9% of patients achieved EASI75 with galvokimig versus 12.3% with placebo.” ucb.com ↗

Drugs

Indications